Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Genz-123346 is a glucosylceramide synthase inhibitor (IC50 = 14 nM).1 It reduces hepatic levels of glucosylceramide and triglycerides as well as blood levels of alanine aminotransferase (ALT), hemoglobin A1c, and non-fasting glucose in ob/ob mice when administered at a dose of 120 mg/kg per day.2 Genz-123346 (125 mg/kg per day) also decreases hepatic fat mass and reduces the size and number of hepatic lipid droplets in diet-induced obese mice.
WARNING This product is not for human or veterinary use.
1. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56(5), 1210-1218 (2007).
2. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50(1), 85-93 (2009).